Altasciences’ Clinical Facilities Move in Unison

Altasciences provides strategically located clinical pharmacology facilities and access to over 500 beds across North America. We have over 1,000 employees dedicated to clinical pharmacology research who conduct over 285 trials per year. 

Operations at our clinical teams in Los Angeles, Kansas City, and Montreal follow the same set of standard operating procedures to offer you a scientifically sound, quality experience, every time — for both your single-site or multi-site studies.  

In addition, our clinical teams work in unison with our preclinical, bioanalytical, manufacturing, and research support teams at our five other sites, to offer an integrated drug development solution, from lead candidate selection to clinical proof of concept, and beyond.

Altasciences provides customized solutions that fit your needs, and innovative in-house recruitment call centers for quick study startup.

Let’s get started!

You may also be interested in the following:

• Video: Fully Integrated Drug Development Solutions
• Webpage: Phase 1 Clinical Trial Units 
• E-book: First-in-Human Solution 

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

It’s All About ASOs!

Antisense oligonucleotides (ASOs) offer an exciting pathway to targeting the source of a disease’s pathogenesis. In this e-book, we take a deep dive into the bioanalytical development for the analysis of ASOs.

Topics covered: 

• Benefits and challenges of novel ASO bioanalytical approaches.
• Case studies examining how best to align a bioanalytical technique with the goals of a particular ASO drug development program. 

Download the FREE e-book now

Speak with an expert.

Have 5 minutes? Take a look at these:

• Comprehensive Bioanalytical Services
• Altasciences' Proprietary Bioanalytical Assay List
• Three Laboratories – One Vision (PODCAST)

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

40% of marketed drugs and 90% of active pharmaceutical ingredients (APIs) are poorly water-soluble, BCS Class II or IV. Nanomilling is a proven technique that can overcome solubility challenges and ensure your molecules are developed successfully into life-saving therapies. 

In our latest ​​​​​​ issue of The Altascientist, learn about:

• Solubility classifications (consult the checklist to see if your API qualifies)
• How nanomilling works
• The advantages of nanomilling
• Maximizing formulations
• A case study

Download your copy today, or listen to the audio recording.
 

Questions? Speak with our experts.

Moving in Unison to Bring Your Vision to Life 

Trust is an important factor in any relationship. And we know trust is earned. 

That’s why at Altasciences, our focus is on you. We build strong relationships with each client through quality science and  proactive, responsive, and transparent communication that ensures you only have to Tell Us Once™. 

When you choose us, you are choosing a partner that will work as an extension of your team — who treats you like colleagues and your projects as our own. We’ll work side by side, getting to know your goals and understanding your needs. From preclinical to clinical proof of concept, and beyond, we’ll advance your molecule in one integrated, seamless process, celebrating your milestones together. 

Why? Because drug development isn’t a transaction — it’s a journey. Speak with an Altasciences expert to start your journey.
 

Watch this video to discover what it means to partner with Altasciences:

Have five minutes? Take a look at these: 

• Check out our new interactive brochure
• Discover our Proactive Drug Development solution
• Read this blog article: Moving Your Drug Forward to Preclinical Trials
• Explore our customizable and flexible early phase solution offering
• Read this Q&A featuring Marie-Hélène Raigneau, our Co-Chief Operating Officer​​​​​

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Episode 2 — The Many Faces of Recreational Drug Use 

Prescription drug abuse has been an ongoing public health concern in North America.  In this second episode of "Chasing the Dragon — A Series of Candid Interviews with Opioid and Stimulant Recreational Drug Users”, you will hear from an individual who began using opioids following a back injury. Then, Altasciences’ Dr. Beatrice Setnik, CSO, and Dr. Debra Kelsh, Psychiatrist and Principal Investigator, provide a unique perspective around the behaviors of drug abuse. 

See the second episode: 

In case you missed it, watch Episode 1 here.

Speak with an expert about your research needs.

You may also be interested in the following:

• The Altascientist: CNS-Active Drugs — Complex Considerations
• Webpage: Human Abuse Potential Capabilities
• E-book: First-In-Human Solution

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.